This study aims to evaluate the pharmacokinetic interactions between HUC2-744-A and HUC2-744-B following monotherapy or co-administration under multiple-dose conditions.
For selected subjects, the designated investigational products are administered orally with 200 mL of water during Treatment 1 (HUC2-744-A), Treatment 2 (HUC2-744-B), and Treatment 3 (HUC2-744-A + HUC2-744-B).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
28
HUC2-744-A
HUC2-744-B
Korea University Anam Hospital
Seoul, Seongbuk-gu, South Korea
AUCτ
Area Under the Curve of telmisartan, atorvastatin
Time frame: Day 22
Cmax,ss
Maximum concentration at steady state of telmisartan, atorvastatin
Time frame: Day 22
Cmax,ss
Maximum concentration at steady state of 2-hydroxy atorvastatin
Time frame: Day 22
AUCτ
Area Under the Curve of 2-hydroxy atorvastatin
Time frame: Day 22
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.